Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?

Concerns have been raised about potential toxic interactions when colony-stimulating factors (CSFs) and chemoradiation are concurrently performed. In 2006, the ASCO guidelines advised against their concomitant use. Nevertheless, with the development of modern radiotherapy techniques and supportive c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of radiology 2020-05, Vol.93 (1109), p.20190147
Hauptverfasser: Benna, Marouan, Guy, Jean-Baptiste, Bosacki, Claire, Jmour, Omar, Ben Mrad, Majed, Ogorodniitchouk, Oleksandr, Soltani, Saïd, Lan, Meiling, Daguenet, Elisabeth, Mery, Benoîte, Sotton, Sandrine, Magné, Nicolas, Vallard, Alexis
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1109
container_start_page 20190147
container_title British journal of radiology
container_volume 93
creator Benna, Marouan
Guy, Jean-Baptiste
Bosacki, Claire
Jmour, Omar
Ben Mrad, Majed
Ogorodniitchouk, Oleksandr
Soltani, Saïd
Lan, Meiling
Daguenet, Elisabeth
Mery, Benoîte
Sotton, Sandrine
Magné, Nicolas
Vallard, Alexis
description Concerns have been raised about potential toxic interactions when colony-stimulating factors (CSFs) and chemoradiation are concurrently performed. In 2006, the ASCO guidelines advised against their concomitant use. Nevertheless, with the development of modern radiotherapy techniques and supportive care, the therapeutic index of combined chemotherapy, radiotherapy, and CSFs is worth reassessing. Recent clinical trials testing chemoradiation in lung cancer let investigators free to decide the use of concomitant CSFs or not. No abnormal infield event was reported after the use of modern radiotherapy techniques and concomitant chemotherapy regimens. These elements call for further investigation to set new recommendations in favour of the association of chemoradiation and CSFs. Moreover, radiotherapy could induce anticancer systemic effects mediated by the immune system and . With combined CSFs, this effect was reinforced in preclinical and clinical trials introducing innovative radioimmunotherapy models. So far, the association of radiation with CSFs has not been combined with immunotherapy. However, it might play a major role in triggering an immune response against cancer cells, leading to abscopal effects. The present article reassesses the therapeutic index of the combination CSFs-chemoradiation through an updated review on its safety and efficacy. It also provides a special focus on radioimmunotherapy.
doi_str_mv 10.1259/bjr.20190147
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7217575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31971824</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-47541daf01f14890b064ddc2ac4eb249091f8c18b4c695c11d9a254adf6a5dcc3</originalsourceid><addsrcrecordid>eNpVUcFKw0AQXUSxtXrzLHtUMHUn2W2yHhQJtgoVDyp4C5vdTZqaZMtmI_Yb_GkTaoueZt7Me29gHkKnQMbgM36VLu3YJ8AJ0HAPDSGkkRdF5H0fDQkhoQd-xAboqGmWPWScHKJBADyEyKdD9B0vdGWsUIVwhamxqBXOrajb0si10540panX2Ni_U1wJac1qIfIdoXFF1ZadR53jTEhnbIPPZ178Mu21s6e-u7jGHUtjZ7BbFPUHNq3DJuuAxqn5uj1GB5koG33yW0fobXr_Gj948-fZY3w392TAwHk0ZBSUyAhkQCNOUjKhSklfSKpTn3LCIYskRCmVE84kgOLCZ1SobCKYkjIYoZuN76pNK62krp0VZbKyRSXsOjGiSP5v6mKR5OYzCX0IWcg6g8uNQfeFprE622mBJH0oSRdKsg2lo5_9vbcjb1MIfgBq-ott</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Benna, Marouan ; Guy, Jean-Baptiste ; Bosacki, Claire ; Jmour, Omar ; Ben Mrad, Majed ; Ogorodniitchouk, Oleksandr ; Soltani, Saïd ; Lan, Meiling ; Daguenet, Elisabeth ; Mery, Benoîte ; Sotton, Sandrine ; Magné, Nicolas ; Vallard, Alexis</creator><creatorcontrib>Benna, Marouan ; Guy, Jean-Baptiste ; Bosacki, Claire ; Jmour, Omar ; Ben Mrad, Majed ; Ogorodniitchouk, Oleksandr ; Soltani, Saïd ; Lan, Meiling ; Daguenet, Elisabeth ; Mery, Benoîte ; Sotton, Sandrine ; Magné, Nicolas ; Vallard, Alexis</creatorcontrib><description>Concerns have been raised about potential toxic interactions when colony-stimulating factors (CSFs) and chemoradiation are concurrently performed. In 2006, the ASCO guidelines advised against their concomitant use. Nevertheless, with the development of modern radiotherapy techniques and supportive care, the therapeutic index of combined chemotherapy, radiotherapy, and CSFs is worth reassessing. Recent clinical trials testing chemoradiation in lung cancer let investigators free to decide the use of concomitant CSFs or not. No abnormal infield event was reported after the use of modern radiotherapy techniques and concomitant chemotherapy regimens. These elements call for further investigation to set new recommendations in favour of the association of chemoradiation and CSFs. Moreover, radiotherapy could induce anticancer systemic effects mediated by the immune system and . With combined CSFs, this effect was reinforced in preclinical and clinical trials introducing innovative radioimmunotherapy models. So far, the association of radiation with CSFs has not been combined with immunotherapy. However, it might play a major role in triggering an immune response against cancer cells, leading to abscopal effects. The present article reassesses the therapeutic index of the combination CSFs-chemoradiation through an updated review on its safety and efficacy. It also provides a special focus on radioimmunotherapy.</description><identifier>ISSN: 0007-1285</identifier><identifier>EISSN: 1748-880X</identifier><identifier>DOI: 10.1259/bjr.20190147</identifier><identifier>PMID: 31971824</identifier><language>eng</language><publisher>England: The British Institute of Radiology</publisher><subject>Animals ; Chemoradiotherapy - adverse effects ; Clinical Trials, Phase III as Topic ; Combined Modality Therapy ; Disease Models, Animal ; Granulocyte Colony-Stimulating Factor - adverse effects ; Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects ; Humans ; Lung Neoplasms - therapy ; Mice ; Radioimmunotherapy - adverse effects ; Randomized Controlled Trials as Topic ; Review ; Small Cell Lung Carcinoma - therapy</subject><ispartof>British journal of radiology, 2020-05, Vol.93 (1109), p.20190147</ispartof><rights>2020 The Authors. Published by the British Institute of Radiology 2020 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-47541daf01f14890b064ddc2ac4eb249091f8c18b4c695c11d9a254adf6a5dcc3</citedby><cites>FETCH-LOGICAL-c351t-47541daf01f14890b064ddc2ac4eb249091f8c18b4c695c11d9a254adf6a5dcc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31971824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Benna, Marouan</creatorcontrib><creatorcontrib>Guy, Jean-Baptiste</creatorcontrib><creatorcontrib>Bosacki, Claire</creatorcontrib><creatorcontrib>Jmour, Omar</creatorcontrib><creatorcontrib>Ben Mrad, Majed</creatorcontrib><creatorcontrib>Ogorodniitchouk, Oleksandr</creatorcontrib><creatorcontrib>Soltani, Saïd</creatorcontrib><creatorcontrib>Lan, Meiling</creatorcontrib><creatorcontrib>Daguenet, Elisabeth</creatorcontrib><creatorcontrib>Mery, Benoîte</creatorcontrib><creatorcontrib>Sotton, Sandrine</creatorcontrib><creatorcontrib>Magné, Nicolas</creatorcontrib><creatorcontrib>Vallard, Alexis</creatorcontrib><title>Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?</title><title>British journal of radiology</title><addtitle>Br J Radiol</addtitle><description>Concerns have been raised about potential toxic interactions when colony-stimulating factors (CSFs) and chemoradiation are concurrently performed. In 2006, the ASCO guidelines advised against their concomitant use. Nevertheless, with the development of modern radiotherapy techniques and supportive care, the therapeutic index of combined chemotherapy, radiotherapy, and CSFs is worth reassessing. Recent clinical trials testing chemoradiation in lung cancer let investigators free to decide the use of concomitant CSFs or not. No abnormal infield event was reported after the use of modern radiotherapy techniques and concomitant chemotherapy regimens. These elements call for further investigation to set new recommendations in favour of the association of chemoradiation and CSFs. Moreover, radiotherapy could induce anticancer systemic effects mediated by the immune system and . With combined CSFs, this effect was reinforced in preclinical and clinical trials introducing innovative radioimmunotherapy models. So far, the association of radiation with CSFs has not been combined with immunotherapy. However, it might play a major role in triggering an immune response against cancer cells, leading to abscopal effects. The present article reassesses the therapeutic index of the combination CSFs-chemoradiation through an updated review on its safety and efficacy. It also provides a special focus on radioimmunotherapy.</description><subject>Animals</subject><subject>Chemoradiotherapy - adverse effects</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Combined Modality Therapy</subject><subject>Disease Models, Animal</subject><subject>Granulocyte Colony-Stimulating Factor - adverse effects</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects</subject><subject>Humans</subject><subject>Lung Neoplasms - therapy</subject><subject>Mice</subject><subject>Radioimmunotherapy - adverse effects</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Review</subject><subject>Small Cell Lung Carcinoma - therapy</subject><issn>0007-1285</issn><issn>1748-880X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUcFKw0AQXUSxtXrzLHtUMHUn2W2yHhQJtgoVDyp4C5vdTZqaZMtmI_Yb_GkTaoueZt7Me29gHkKnQMbgM36VLu3YJ8AJ0HAPDSGkkRdF5H0fDQkhoQd-xAboqGmWPWScHKJBADyEyKdD9B0vdGWsUIVwhamxqBXOrajb0si10540panX2Ni_U1wJac1qIfIdoXFF1ZadR53jTEhnbIPPZ178Mu21s6e-u7jGHUtjZ7BbFPUHNq3DJuuAxqn5uj1GB5koG33yW0fobXr_Gj948-fZY3w392TAwHk0ZBSUyAhkQCNOUjKhSklfSKpTn3LCIYskRCmVE84kgOLCZ1SobCKYkjIYoZuN76pNK62krp0VZbKyRSXsOjGiSP5v6mKR5OYzCX0IWcg6g8uNQfeFprE622mBJH0oSRdKsg2lo5_9vbcjb1MIfgBq-ott</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Benna, Marouan</creator><creator>Guy, Jean-Baptiste</creator><creator>Bosacki, Claire</creator><creator>Jmour, Omar</creator><creator>Ben Mrad, Majed</creator><creator>Ogorodniitchouk, Oleksandr</creator><creator>Soltani, Saïd</creator><creator>Lan, Meiling</creator><creator>Daguenet, Elisabeth</creator><creator>Mery, Benoîte</creator><creator>Sotton, Sandrine</creator><creator>Magné, Nicolas</creator><creator>Vallard, Alexis</creator><general>The British Institute of Radiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200501</creationdate><title>Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?</title><author>Benna, Marouan ; Guy, Jean-Baptiste ; Bosacki, Claire ; Jmour, Omar ; Ben Mrad, Majed ; Ogorodniitchouk, Oleksandr ; Soltani, Saïd ; Lan, Meiling ; Daguenet, Elisabeth ; Mery, Benoîte ; Sotton, Sandrine ; Magné, Nicolas ; Vallard, Alexis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-47541daf01f14890b064ddc2ac4eb249091f8c18b4c695c11d9a254adf6a5dcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Chemoradiotherapy - adverse effects</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Combined Modality Therapy</topic><topic>Disease Models, Animal</topic><topic>Granulocyte Colony-Stimulating Factor - adverse effects</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects</topic><topic>Humans</topic><topic>Lung Neoplasms - therapy</topic><topic>Mice</topic><topic>Radioimmunotherapy - adverse effects</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Review</topic><topic>Small Cell Lung Carcinoma - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Benna, Marouan</creatorcontrib><creatorcontrib>Guy, Jean-Baptiste</creatorcontrib><creatorcontrib>Bosacki, Claire</creatorcontrib><creatorcontrib>Jmour, Omar</creatorcontrib><creatorcontrib>Ben Mrad, Majed</creatorcontrib><creatorcontrib>Ogorodniitchouk, Oleksandr</creatorcontrib><creatorcontrib>Soltani, Saïd</creatorcontrib><creatorcontrib>Lan, Meiling</creatorcontrib><creatorcontrib>Daguenet, Elisabeth</creatorcontrib><creatorcontrib>Mery, Benoîte</creatorcontrib><creatorcontrib>Sotton, Sandrine</creatorcontrib><creatorcontrib>Magné, Nicolas</creatorcontrib><creatorcontrib>Vallard, Alexis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Benna, Marouan</au><au>Guy, Jean-Baptiste</au><au>Bosacki, Claire</au><au>Jmour, Omar</au><au>Ben Mrad, Majed</au><au>Ogorodniitchouk, Oleksandr</au><au>Soltani, Saïd</au><au>Lan, Meiling</au><au>Daguenet, Elisabeth</au><au>Mery, Benoîte</au><au>Sotton, Sandrine</au><au>Magné, Nicolas</au><au>Vallard, Alexis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?</atitle><jtitle>British journal of radiology</jtitle><addtitle>Br J Radiol</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>93</volume><issue>1109</issue><spage>20190147</spage><pages>20190147-</pages><issn>0007-1285</issn><eissn>1748-880X</eissn><abstract>Concerns have been raised about potential toxic interactions when colony-stimulating factors (CSFs) and chemoradiation are concurrently performed. In 2006, the ASCO guidelines advised against their concomitant use. Nevertheless, with the development of modern radiotherapy techniques and supportive care, the therapeutic index of combined chemotherapy, radiotherapy, and CSFs is worth reassessing. Recent clinical trials testing chemoradiation in lung cancer let investigators free to decide the use of concomitant CSFs or not. No abnormal infield event was reported after the use of modern radiotherapy techniques and concomitant chemotherapy regimens. These elements call for further investigation to set new recommendations in favour of the association of chemoradiation and CSFs. Moreover, radiotherapy could induce anticancer systemic effects mediated by the immune system and . With combined CSFs, this effect was reinforced in preclinical and clinical trials introducing innovative radioimmunotherapy models. So far, the association of radiation with CSFs has not been combined with immunotherapy. However, it might play a major role in triggering an immune response against cancer cells, leading to abscopal effects. The present article reassesses the therapeutic index of the combination CSFs-chemoradiation through an updated review on its safety and efficacy. It also provides a special focus on radioimmunotherapy.</abstract><cop>England</cop><pub>The British Institute of Radiology</pub><pmid>31971824</pmid><doi>10.1259/bjr.20190147</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1285
ispartof British journal of radiology, 2020-05, Vol.93 (1109), p.20190147
issn 0007-1285
1748-880X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7217575
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects Animals
Chemoradiotherapy - adverse effects
Clinical Trials, Phase III as Topic
Combined Modality Therapy
Disease Models, Animal
Granulocyte Colony-Stimulating Factor - adverse effects
Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects
Humans
Lung Neoplasms - therapy
Mice
Radioimmunotherapy - adverse effects
Randomized Controlled Trials as Topic
Review
Small Cell Lung Carcinoma - therapy
title Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A28%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemoradiation%20and%20granulocyte-colony%20or%20granulocyte%20macrophage-colony%20stimulating%20factors%20(G-CSF%20or%20GM-CSF):%20time%20to%20think%20out%20of%20the%20box?&rft.jtitle=British%20journal%20of%20radiology&rft.au=Benna,%20Marouan&rft.date=2020-05-01&rft.volume=93&rft.issue=1109&rft.spage=20190147&rft.pages=20190147-&rft.issn=0007-1285&rft.eissn=1748-880X&rft_id=info:doi/10.1259/bjr.20190147&rft_dat=%3Cpubmed_cross%3E31971824%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31971824&rfr_iscdi=true